To hear about similar clinical trials, please enter your email below
Trial Title:
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
NCT ID:
NCT01373736
Condition:
Pheochromocytoma
Neuroblastoma
Paraganglioma
Medullary Thyroid Carcinoma
Carcinoid Tumors
Conditions: Official terms:
Neuroblastoma
Carcinoid Tumor
Thyroid Neoplasms
Pheochromocytoma
Paraganglioma
3-Iodobenzylguanidine
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Unknown status
Study design:
Primary purpose:
Diagnostic
Intervention:
Intervention type:
Drug
Intervention name:
123I-meta-iodobenzylguanidine
Summary:
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic
imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the
presence, extent, or status of neuroendocrine tumors;
- subjects must be able and willing to comply with study procedures.
Exclusion Criteria:
- Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL
[265 µmol/L]) and inability to be withdrawn from medications known to interfere with
123I-MIBG uptake;
- Subjects unable to tolerate lying supine;
- Subjects pregnant or breastfeeding, unless the information to be gained outweighs
the possible hazardous effects of 123I-MIBG administration. Where the assessment of
the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the
breastfeeding should be discontinued for at least 48 hours post-injection.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Vancouver Coastal Health
Address:
City:
Vancouver
Zip:
V5Z1M9
Country:
Canada
Lead sponsor:
Agency:
Vancouver Coastal Health
Agency class:
Other
Source:
Vancouver Coastal Health
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01373736
